期刊文献+

Anti-hepatitis B virus activities of natural products and their antiviral mechanisms

原文传递
导出
摘要 Chronic hepatitis B (CHB) infections caused by the hepatitis B virus (HBV) continue to pose a significant global public health challenge. Currently, the approved treatments for CHB are limited to interferon and nucleos(t)ide analogs, both of which have their limitations, and achieving a complete cure remains an elusive goal. Therefore, the identification of new therapeutic targets and the development of novel antiviral strategies are of utmost importance. Natural products (NPs) constitute a class of substances known for their diverse chemical structures, wide-ranging biological activities, and low toxicity profiles. They have shown promise as potential candidates for combating various diseases, with a substantial number demonstrating anti-HBV properties. This comprehensive review focuses on the current applications of NPs in the fight against HBV and provides a summary of their antiviral mechanisms, considering their impact on the viral life cycle and host hepatocytes. By offering insights into the world of anti-HBV NPs, this review aims to furnish valuable information to support the future development of antiviral drugs.
出处 《Chinese Journal of Natural Medicines》 SCIE CSCD 2023年第11期803-811,共9页 中国天然药物(英文版)
基金 supported by the National Natural Science Foundation of China(No.82260603) the Natural Science Foundation of Jiangxi province(No.20224BAB206005) Shenzhen Institute of Synthetic Biology,Shenzhen Institutes of Advanced Technology,Chinese Academy of Sciences(No.ZXXM20190001/ZXXM20200001/ZXXM20220001)。
  • 相关文献

参考文献6

二级参考文献53

  • 1Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int 2011, 5: 644-53.
  • 2Negro F. Management of chronic hepatitis B: an update. Swiss Med Wkly 2011, 141: w13264.
  • 3Leemans WF, Ter Borg M J, de Man RA. Review article: success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. Aliment Pharmacol Ther 2007, 26 Suppl 2: 171-82.
  • 4Lucifora J, Zoulim F. The life cycle of hepatitis B virus and antiviral targets. Future Viro12011, 6: 599-614.
  • 5Choi IG, Yu YG. Interaction and assembly of HBV structural proteins: novel target sites of anti-HBV agents. Infect Disord Drug Targets 2007, 7: 251-6.
  • 6Chen H J, Wang WL, Wang GF, Shi LP, Gu M, Ren YD, et al. Rational design and synthesis of 2,2-bisheterocycle tandem derivatives as non-nucleoside hepatitis B virus inhibitors. Chem Med Chem 2008, 3: 1316-21.
  • 7Deres K, Schroder CH, Paessens A, Goldmann S, Hacker H J, Weber O, et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003, 299: 893-6.
  • 8Ying C, Li Y, Leung CH, Robek MD, Cheng YC. Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc Natl Acad Sci U S A 2007, 104: 8526-31.
  • 9Wu C, DengW, Deng L, Cao L, Qin B, Li S, et al. Amino acid substitutions at positions 122 and 145 of hepatitis B virus surface antigen (HBsAg) determine the antigenicity and immunogenicity of HBsAg and influence in vivo HBsAg clearance. J Virol 2012, 86: 4658-69.
  • 10Newman M, Chua PK, Tang FM, Su PY, Shih C. Testing an electrostatic interaction hypothesis of hepatitis B virus capsid stability by using an in vitro capsid disassembly/reassembly system. J Virol 2009, 83: 10616-26.

共引文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部